BioLife Solutions issued a press release August 8, 2019, announcing the execution of a share exchange agreement to purchase the remaining 56% of shares of SAVSU Technologies that BioLife did not previously own. BioLife’s relationship with Savsu spans six years, during the development and growth of the evo® Cold Chain 2.0™ system, encompassing evo® hardware…
Read More
We’re Joining Forces! BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU spans…
Read More
Posters presenting data for T-cells cryopreserved in CryoStor® cryopreservation solution, authored by BioLife Solutions’ Alireza Abazari, Ph.D., Scientific Applications Director and Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, were featured during the International Society for Cell & Gene Therapy meeting in Melbourne, Australia, May 29 – June 1, 2019. View the…
Read More
Implementation of Biopreservation Best Practices to Address a Critical Component of Cell & Gene Therapy Manufacturing Hosted by Cell and Gene Therapy Insights Implementation of best practices in formulation can directly address multiple process bottlenecks including: GMP compliance, minimizing freezing damage, support stability during storage and against transient warming events, support post-thaw stability, and excipient…
Read More Heading to the ISCT Annual Meeting in Melbourne? Bring us your Biopreservation Challenges. If you’re headed to the 2019 ISCT Meeting in Melbourne, join us in BOOTH 84 and learn how we’re strengthening our mission to provide the best cell and gene therapy tools in the industry. Our expanding platform of biopreservation tools now includes…
Read More
According to data provided by the Alliance for Regenerative Medicine, there are nearly 900 companies responsible for more than 1000 industry-sponsored clinical trials within regenerative medicine utilizing advanced therapeutics including cell, gene, and tissue engineered products. Maintaining oversight on these precious therapies, literally vein-to-vein, encompassing a multitude of stakeholders, lengthy timelines, across countries and continents…
Read More
Disease models facilitate understanding the pathogenesis of disease, identification and development of potential interventions and evaluation of new treatments. BioLife Solutions maintains an online, searchable, Evidence Library that contains over 365 articles, abstracts and posters citing Biopreservation efficacy of CryoStor® and HypoThermosol®. Recently added to the Evidence Library, the journal article authored by Xinyue Bai…
Read More
One of the benefits of cryopreserving cells is the flexibility in scheduling for later use that freezing provides. Determining the optimal solution for cryopreservation that consistently results in post-thaw recovery of the greatest number of highly viable, functional cells is crucial. The article by Sara S. Parker et al. published in eNeuro and recently added…
Read More
On November 21, 2018, BioLife’s customer Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced that it has dosed its first patient in its pivotal US Phase III clinical trials for Invossa, a cell and gene therapy in development for knee osteoarthritis (OA). “This is an exciting step for Kolon TissueGene as we…
Read More Mesenchymal Stem Cells have been the cell type of interest for the following articles recently entered into BioLife’s growing Evidence library. 1. Sutton, M. T., Kaur, S., Brown, K. S., Skiles, M. L., Folz, M. A., Caplan, A. I. and Bonfield, T. L.. (2018). Anti-Inflammatory Therapeutic Development and Optimization of Umbilical Cord Tissue Derived Mesenchymal…
Read More